Table 1.
Patient characterstics by site
| CMH/F H- Argenti na (n=58) |
FC- Brazil (n=138) |
FA-Chile (n=28) |
IHSS/HE - Hondur as (n=27) |
INMNSZ- Mexico (n=34) |
VCCC- United States (n=55) |
CCASA net (n=28 5) |
Combin ed (n=340) |
p- value * |
|
|---|---|---|---|---|---|---|---|---|---|
| Patient age at enrollment (years) | 35 (31–39) | 35 (29 – 41) | 34 (28–43) | 37 (31 – 43) | 35 (29 – 44) | 41 (36 – 45) | 35 (29 – 41) | 36 (30 – 43) | <0.001 |
| Male sex | 51 (88%) | 105 (76%) | 26 (93%) | 16 (59%) | 29 (85%) | 44 (80%) | 227 (80%) | 271 (80%) | 1.000 |
| CD4 at enrollment | 46 (19–75) | 111 (40 – 242) | 46 (4–104) | 50 (45 – 110) | 37 (13 – 96) | 29 (8 – 58) | 51 (21 – 132) | 46 (15 – 105) | <0.001 |
| Missing CD4 at enrollment, n(%) | 34 (59%) | 92 (67%) | 19 (68%) | 10 (37%) | 1 (3%) | 0 (0%) | 156 (55%) | 156 (46%) | |
| CD4 at diagnosis of CM | 22 (13–45) | 83 (31 – 182) | 86 (10–142) | 65 (45 – 150) | 28 (10 – 51) | 38 (11 – 69) | 47 (17 – 112) | 45 (16 – 100) | 0.065 |
| Missing CD4 at diagnosis of CM, n(%) | 26 (45%) | 61 (44%) | 14 (50%) | 8 (30%) | 1 (3%) | 21 (38%) | 110 (39%) | 131 (39%) | |
| CD4 at ART initiation | 30 (14–65) | 110 (43 – 251) | 30 (7–88) | 50 (32 – 102) | 31 (13 – 51) | 56 (17 – 90) | 51 (24 – 128) | 51 (22 – 124) | 0.495 |
| Missing CD4 at ART initiation, n(%) | 25 (43%) | 68 (49%) | 16 (57%) | 3 (11%) | 9 (26%) | 20 (36%) | 121 (42%) | 141 (41%) | |
| Route of HIV transmission, n(%) | 0.442 | ||||||||
| Heterosexual | 16 (28%) | 50 (36%) | 9 (32%) | 16 (59%) | 13 (38%) | 24 (44%) | 104 (36%) | 128 (38%) | |
| MSM | 18 (31%) | 53 (38%) | 18 (64%) | 1 (4%) | 20 (59%) | 16 (29%) | 110 (39%) | 126 (37%) | |
| Other | 19 (33%) | 9 (7%) | 1 (4%) | 0 (0%) | 0 (0%) | 8 (15%) | 29 (10%) | 37 (11%) | |
| Unknown | 5 (9%) | 26 (19%) | 0 (0%) | 10 (37%) | 1 (3%) | 7 (13%) | 42 (15%) | 49 (14%) | |
| Deaths | 11 (19%) | 85 (62%) | 6 (21%) | 9 (33%) | 13 (38%) | 18 (33%) | 124 (44%) | 142 (42%) | 0.182 |
| Never started on ART | 1 (2%) | 14 (10%) | 3 (11%) | 2 (7%) | 4 (12%) | 3 (5%) | 24 (8%) | 27 (8%) | 0.636 |
| CM before ART initiation | 27 (47%) | 29 (21%) | 9 (32%) | 15 (56%) | 10 (29%) | 34 (62%) | 90 (32%) | 124 (36%) | <0.001 |
| Days from diagnosis of CM to ART initiation (a) | 29 (22 – 72) | 31 (13 – 61) | 59 (24 – 76) | 39 (11 – 106) | 40 (32 – 51) | 58 (32 – 214) | 33 (14 – 73) | 40 (23.5 – 94.5) | 0.002 |
| CM after ART initiation | 30 (52%) | 95 (69%) | 16 (57%) | 10 (37%) | 20 (59%) | 18 (33%) | 171 (60%) | 189 (56%) | <0.001 |
| Days from ART initiation to diagnosis of CM (b) | 1025 (168 – 2383) | 832 (125 – 2404) | 986 (215 – 1822) | 69 (40 – 546) | 363 (80 – 2806) | 734 (122 – 1997) | 743 (97 – 2282) | 743 (98 – 2274) | 0.888 |
| Follow-up after CM (years) | 4 (0.8 – 8) | 3 (0.2 – 6) | 6.6 (3 – 9) | 6.3 (1.6 – 8.4) | 1.3 (0.3 – 4.5) | 3.5 (1.4 – 7) | 3.5 (0.5– 7.5) | 3.5 (0.7–7.5) | 0.39 |
p-values between CCASAnet and Vanderbilt
Continuous variables are reported as medians (interquartile range)
CMH/FH-Argentina- Centro Medico Huesped/Hospital Fernandez, Buenos Aires, Argentina
FC-Brazil- Instituto de Pesquisa Clinica Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
FA-Chile- Fundación Arriarán, Santiago, Chile
IHSS/HE-Honduras- ); Instituto Hondureño de Seguridad Social and Hospital Escuela, Tegucigalpa, Honduras
INMNSZ-Mexico- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
VCCC- US Vanderbilt Comprehensive Care Clinic, Nashville, Tennessee, U.S.A.
CM Cryptococcal meningitis
MSM- Men who have sex with men
Time to ARV estimated only in patients with a cryptococcosis event reported before ARV initiation.
Time since ARV initiation to cryptococcosis event estimated only in patients with a cryptococcosis event reported after ARV initiation.